MU

At $903.70, Micron trades at 12.16x trailing earnings, 5.12x current-fiscal-year consensus EPS of $176.58, 4.37x next-fiscal-year consensus EPS of $206.89, a 0.16 PEG, 7.39x book, 8.77x EV/EBITDA and 7.68x sales, with enterprise value of $954.63 billion equal to 0.93x the $1.02 trillion market capitalization. The forward multiples and PEG screen as deeply undervalued if those estimates are achievable, and the revision tape still supports them: next-fiscal-year consensus has been raised 15.39% in 30 days (from $179.31) and 26.98% in 90 days (from $162.94), while current-fiscal-year consensus has risen 10.60% in 30 days and 14.77% in 90 days. Note that the forward multiple has actually expanded from 4.24x to 4.37x purely because the share price rose 2.98% — the earnings estimate itself was unchanged over the past seven days. The cyclical caveat dominates: an 80.72% gross margin is not a through-cycle level for a DRAM/NAND manufacturer, and a 7.68x price-to-sales multiple is demanding against only 3.79% reported year-over-year revenue growth, meaning current earnings power derives almost entirely from pricing and mix rather than volume. No peer-multiple set or cycle-normalized valuation history is supplied, so a discount to semiconductor peers cannot be verified. The stock is optically cheap on near-term earnings but not demonstrably cheap on normalized earnings power, and the $361 low analyst target (-60.1%) is an explicit statement that at least one desk models a materially lower cycle.

At $903.70, price remains 7.70% below the 20-day SMA of $979.09 and 6.19% below the 50-day EMA of $963.33, both still falling, so the intermediate downtrend that began at the October 1 closing high of $1,097.22 is technically intact despite the two-day reversal. The tactical development is material: the October 26 close sits above the October 23 high of $891.89 and above the entire $849.25-$877.55 recovery shelf, and the session traded through the prior $908.30 invalidation trigger to $915.75, so the October 22 breakdown has been undone on price even though the close stopped 0.5% shy of $908.30 and volume (22.63 million) missed the 26.92 million 20-day average. The $849.25 October 22 low and $858.34 October 23 low now form a credible double low, and $882.77 is the higher low that defines the reversal. Price is 25.31% above the 200-day EMA of $721.17 and the 50-day EMA remains 33.58% above the 200-day (versus 34.2% three sessions ago), so the golden-cross structure is intact and a death cross is not remotely near; the 200-day EMA at $721.17 is the last structural line of defense and sits 20.2% below the current close. The stock is 28.0% below its $1,255.00 52-week high, 369.2% above its $192.59 low and at the 66.93rd percentile of its 52-week range, up from 64.47th on October 23.

FY26 Q4 EPS of $33.42 beat the $31.82 consensus by 5.03%, the seventh consecutive beat in the supplied history but by far the smallest surprise versus an average of roughly 16.5% (prior surprises were 21.4%, 33.2%, 20.6%, 5.9%, 19.8% and 9.5%), and sequential growth slipped to +33.1% from +105.8% the prior quarter, so the trajectory is still upward while the rate of improvement is clearly flattening; the stock nevertheless fell as low as $849.25 by October 22, a 22.6% drawdown from its October 1 close, indicating the market is discounting future memory pricing rather than reacting to delivered results, and the bundle contains no management guidance record, so the beat sequence is a positive but incomplete proxy for guidance credibility.

The unresolved divergence between price and estimates remains the single most market-moving item in the dataset: next-fiscal-year consensus EPS is up 15.39% in 30 days to $206.89 while the stock sits 17.64% below its October 1 close, and neither the October 22 collapse nor the two-day recovery has an identifiable catalyst because the supplied feed ends September 29. With the recovery now extended to $903.70 and no news to validate it, the December 23 report is the first hard datapoint capable of reconciling price with estimates, and the absence of a named catalyst should be treated as unresolved risk rather than reassurance.

VIX fell 5.45% to 18.39 and the 10-year yield held at 4.986% while the Nasdaq added 0.82% and the S&P 500 added 0.70%, so the de-risking pressure that crushed this 2.226-beta, 49.68%-realized-volatility memory name on October 22 has eased for now, but with VIX still mid-band and the 10-year pinned near 5%, a 4.37x-forward-multiple cyclical remains hostage to any renewed rate or volatility shock.

Micron is a high-quality memory franchise carrying $38.26 billion of net cash (3.74% of the $1.02 trillion market capitalization), an 8.39x cash-to-debt ratio and 17.32x operating-cash-flow-to-debt coverage, plus a strategically critical HBM position, but its 80.72% gross margin and 63.80% net margin are pricing-driven cycle outcomes rather than structural economics given only 3.79% year-over-year revenue growth. A 2.226 beta, a 5.22%-of-price ATR ($47.15), 49.68% 20-day realized volatility and a 28.0% drawdown from the $1,255 52-week high confirm that 20-30% pullbacks are a normal cost of ownership rather than tail events. It belongs in a satellite growth sleeve at one-third to one-half normal weight, with new capital deployed on pullbacks into the $865-$895 shelf rather than chased into the falling 20-day SMA at $979.09. Underwrite this as a cycle-levered earnings stream with an unusually strong balance sheet, not as a compounder.